GSK: positive results for ViiV dual therapy
(CercleFinance.com) - On Thursday, ViiV Healthcare, a GSK subsidiary, unveiled the results of a "positive" phase III clinical study of a new class of HIV drug.
ViiV reported that its dual therapy of cabotegravir and rilpivirine (Janssen), injectable once every two months to treat HIV-1, has been as effective as a monthly injection over 48 weeks.
The once-a-month injectable dual therapy based on cabotegravir and rilpivirine to treat HIV-1 in adults with virological suppression is subject to a priority review by the US FDA, with a decision due by the end of the year.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
ViiV reported that its dual therapy of cabotegravir and rilpivirine (Janssen), injectable once every two months to treat HIV-1, has been as effective as a monthly injection over 48 weeks.
The once-a-month injectable dual therapy based on cabotegravir and rilpivirine to treat HIV-1 in adults with virological suppression is subject to a priority review by the US FDA, with a decision due by the end of the year.
Copyright (c) 2019 CercleFinance.com. All rights reserved.